ArticleFrontiers in oncology2026
Stable disease after multimodal treatment of SMARCA4-deficient undifferentiated tumor concurrently involving the stomach and mediastinum: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a clinically rare SMARCA4-deficient undifferentiated tumor concurrently involving the stomach and mediastinum. A 54-year-old man presented with a 1-month history of left upper abdominal pain radiating to the anterior chest and back. Contrast-enhanced computed tomography of the chest and abdomen showed thickening and abnormal enhancement of the gastric wall along the greater curvature, multiple enlarged lymph nodes along the lesser curvature, and a posterior inferior mediastinal mass. Biopsies of both the gastric body lesion and the mediastinal mass revealed a poorly differentiated/undifferentiated malignant tumor, and additional immunohistochemistry supported SMARCA4/BRG1-deficient undifferentiated tumor at both sites. The similar undifferentiated morphology and loss of SMARCA4/BRG1 expression support a possible biological relationship between the two lesions but do not establish the primary site, direction of spread, or a shared clonal origin. Because paired molecular profiling, clonality analysis, and phylogenetic analysis were not performed, three possibilities cannot be reliably distinguished: a gastric primary with mediastinal metastasis; a mediastinal primary with gastric involvement or metastasis; and two independent primary tumors of the stomach and mediastinum. The symptomatic mediastinal lesion was treated with local radiotherapy using 6-MV X-rays and image-guided radiotherapy (IGRT), with prescribed doses of 67.2 Gy in 28 fractions to GTVboost, 61.6 Gy in 28 fractions to GTV, and 50.4 Gy in 28 fractions to PTV, together with systemic therapy. Computed tomography after the 25th fraction showed marked shrinkage of the mediastinal lesion, with substantial relief of left upper abdominal and radiating chest and back pain. The patient subsequently received radiotherapy to multiple lesions and several lines of systemic treatment and remained alive with stable disease at the last follow-up. This case highlights the uncertainty in determining the primary site and relationship between lesions when a SMARCA4-deficient undifferentiated tumor concurrently involves the stomach and mediastinum. In symptomatic patients with advanced disease, local radiotherapy combined with systemic treatment may contribute to pain relief and short-term disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.